- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00954915
Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis
February 4, 2022 updated by: MacroGenics
A Phase 2a, Open Label, Multiple-Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Teplizumab in Adults With Moderate or More Severe Psoriasis
The purpose of this study is to determine whether teplizumab is safe when administered subcutaneously (by needle under the skin) in subjects with psoriasis.
The study will also evaluate how long teplizumab stays in the blood and how long it takes for it to leave the body, what is the highest dose that can safely be given, and whether it improves psoriasis.
Study Overview
Detailed Description
This study will test the hypotheses that therapeutic modulation of T-cell function by teplizumab is well tolerated in subjects with moderate or more severe psoriasis, and that this treatment ameliorates the immunopathology of psoriasis.
This study will evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneous (SC) administration for 6 days.
Once the SC maximum tolerated dose is identified, this dose will be administered to a cohort of subject by intravenous for comparison of PK and PD.
Study Type
Interventional
Enrollment (Actual)
1
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan Medical Center
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health & Science University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Chronic plaque psoriasis that has been present for more than 6 months and involves at least 10% Body Surface Area (BSA).
- Baseline LS-PGA score of moderate or greater severity.
- Weight <= 125 kg (276 lb) and a BSA <= 2.5 m^2.
Exclusion Criteria:
- Clinically significant flare of psoriasis during the 12 weeks before enrollment.
- Guttate, erythrodermic, palmoplantar, or pustular (von Zumbusch) psoriasis
- Orally administered systemic psoriasis therapy or phototherapy within the previous 4 weeks; or had topical psoriasis treatment within the previous 2 weeks before enrollment.
- Prior administration of a biologic agent/monoclonal antibody within 12 weeks before enrollment or 5 half-lives of the agent, whichever is greater.
- Prior otelixizumab, OKT®3, or teplizumab.
- Treatment within the last 30 days with a non-biologic drug or device that has not received regulatory approval for any indication at the time of study entry or are unwilling to forgo experimental treatment other than teplizumab during this study.
- Treatment with live vaccine within 8 weeks before enrollment or during study; vaccination with an antigen or killed organism during the study, within 8 weeks before enrollment, or 8 weeks after dosing.
- Evidence of active infection.
- Positive IgM test for hepatitis A.
- History of or positive test for hepatitis B, C, or D.
- History of or positive test for HIV.
- Are immunocompromised, have had recent or current serious systemic or local infection, clinical or radiological evidence of active tuberculosis, or evidence of latent TB infection.
- History of chronic liver disease, peripheral vascular disease, cerebrovascular disease, cardiovascular disease, or epilepsy.
- Current serious or unstable illnesses or allergies.
- Clinically significant laboratory abnormalities.
- Presence of serological reactivity to teplizumab (in subjects previously treated with therapeutic antibodies).
- Clinically significant ECG abnormalities.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: teplizumab
Anti CD-3 monoclonal antibody
|
Cohorts 1-5: escalating doses of subcutaneously administered teplizumab; cohort 6: intravenous administration of maximum tolerated subcutaneous dose.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events (AE)
Time Frame: Day 0 through Day 84
|
Primary endpoints include safety data such as vital signs, physical examinations, electrocardiograms, AE reports, and laboratory test results.
|
Day 0 through Day 84
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Improved on Lattice System Physician's Global Assessment (LS-PGA)
Time Frame: Day 0, 14, 28, 63 and 84
|
The LS-PGA score is determined by estimating the extent of body surface area involved by psoriasis and rating plaque qualities (elevation, erythema, scaling) averaged over the entire body.
LS-PGA score is then determined using available software.
LS-PGA ranks involvement on an 8 point scale from clear, almost clear, mild, mild to moderate, moderate, moderate to severe, severe, and very severe.
Participants who have an improvement of one or more steps in the LS-PGA will be considered to have met the primary criteria for a clinical response.
|
Day 0, 14, 28, 63 and 84
|
Number of Participants Improved on the Psoriasis Area and Severity Index (PASI)
Time Frame: Day 0, 14, 28, 63 and 84
|
The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of plaque scale, erythema, and plaque induration (thickness) in each region, yielding an overall score of 0 for no psoriasis to a maximum of 72 for severe disease.
|
Day 0, 14, 28, 63 and 84
|
Physician's Global Assessment (PGA)
Time Frame: Day 0, 14, 28, 63 and 84
|
The PGA rates the subject's psoriasis relative to baseline as 1 (100% clearing), 2 (excellent: 75% through 99% clearing with striking improvement), 3 (good: 50% through 74% clearing with moderate improvement), 4 (fair: 25% through 49% clearing with slight improvement), 5 (poor: 0% through 24% clearing with little or no change), or 6 (worsening).
Involvement of body-surface area, induration, scaling, and erythema are taken into account.
|
Day 0, 14, 28, 63 and 84
|
Teplizumab Blood Levels
Time Frame: Day 0 through Day 84
|
Day 0 through Day 84
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2009
Primary Completion (Actual)
July 1, 2010
Study Completion (Actual)
July 1, 2010
Study Registration Dates
First Submitted
August 4, 2009
First Submitted That Met QC Criteria
August 6, 2009
First Posted (Estimate)
August 7, 2009
Study Record Updates
Last Update Posted (Actual)
February 10, 2022
Last Update Submitted That Met QC Criteria
February 4, 2022
Last Verified
January 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CP-MGA031-04
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psoriasis
-
ProgenaBiomeRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Face | Psoriasis Nail | Psoriasis Diffusa | Psoriasis Punctata | Psoriasis Palmaris | Psoriasis Circinata | Psoriasis Annularis | Psoriasis Genital | Psoriasis GeographicaUnited States
-
Clin4allRecruitingPsoriasis of Scalp | Psoriasis Nail | Psoriasis Palmaris | Psoriasis Genital | Psoriasis PlantarisFrance
-
Innovaderm Research Inc.CompletedScalp Psoriasis | Pustular Palmo-plantar Psoriasis | Non-pustular Palmo-plantar Psoriasis | Elbow Psoriasis | Lower Leg PsoriasisCanada
-
Centre of Evidence of the French Society of DermatologyRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Palmaris | Psoriatic Erythroderma | Psoriatic Nail | Psoriasis Guttate | Psoriasis Inverse | Psoriasis PustularFrance
-
UCB Biopharma S.P.R.L.CompletedModerate to Severe Psoriasis | Generalized Pustular Psoriasis and Erythrodermic PsoriasisJapan
-
AmgenCompletedPsoriasis-Type Psoriasis | Plaque-Type PsoriasisUnited States
-
TakedaRecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Janssen Pharmaceutical K.K.RecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Eli Lilly and CompanyCompletedGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Shanghai Huaota Biopharmaceutical Co., Ltd.RecruitingGeneralized Pustular Psoriasis (GPP)China
Clinical Trials on teplizumab
-
MacroGenicsEli Lilly and CompanyTerminatedType 1 Diabetes MellitusUnited States, Israel, United Kingdom, Poland, France, Germany, Belgium, Finland, India, Ukraine, Spain, Czechia, Italy, Mexico, Netherlands, Romania
-
Provention Bio, Inc.CompletedType 1 Diabetes MellitusUnited States, Belgium, Canada, Czechia, France, Germany, Hungary, Poland, United Kingdom
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)Terminated
-
Precigen Actobio T1D, LLCTFS Trial Form Support; Intrexon Actobiotics NV, d/b/a Precigen ActobioCompleted
-
Provention Bio, a Sanofi CompanyActive, not recruitingDiabetes Mellitus, Type 1United States, Belgium, Canada, Czechia, France, Germany, Poland, United Kingdom
-
Provention Bio, a Sanofi CompanyCompletedDiabetes Mellitus, Type 1United States
-
National Institute of Diabetes and Digestive and...National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy... and other collaboratorsCompletedImpaired Glucose Tolerance | High Risk | Autoantibody Positive | Non-diabetic Relatives at Risk for Type 1 DiabetesUnited States, Canada, Germany
-
Provention Bio, a Sanofi CompanyRecruitingDiabetes Mellitus, Type 1United States
-
Yale UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Juvenile...Completed
-
MacroGenicsEli Lilly and CompanyTerminatedType 1 Diabetes Mellitus